Glenmark Pharmaceuticals has successfully completed its post-marketing surveillance study on Favipiravir in India. The study commenced in July 2020 to evaluate the safety and efficacy of Favipiravir in mild to moderate COVID-19 patients. Results showed no new safety signals or concerns with the use of Favipiravir, and already-known side effects like weakness, gastritis, diarrhea, vomiting etc were found to be mild in nature. The time for fever resolution was 4 days, while the time for the clinical cure was 7 days.
The study was conducted at thirteen sites - both government and private institutions - across Mumbai, Bangalore, Hyderabad, Nashik, Nagpur, and Trivandrum. It was conducted in patients in line with the approved indication of the drug.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
